Biologics License Application (BLA)

A Biologics License Application (BLA) is the request a sponsor submits to the FDA for permission to market a biological product in the United States. Biologics are large, complex products made from living systems, including monoclonal antibodies, vaccines, blood products and cell and gene therapies.

How it works

BLAs are filed under Section 351 of the Public Health Service Act, rather than the Food, Drug, and Cosmetic Act that governs NDAs. The standard is that the product is safe, pure and potent. Most therapeutic biologics, such as antibodies, are reviewed by the FDA's Center for Drug Evaluation and Research (CDER), while vaccines, blood products and cell and gene therapies go to the Center for Biologics Evaluation and Research (CBER).

The process mirrors an NDA: a 60-day filing review, then a PDUFA date set under standard or priority review, possible advisory committee meetings, and a decision of approval or a complete response letter. Manufacturing scrutiny is often heavier because small process changes can alter a biologic, and pre-license facility inspections are a common source of delays.

Biosimilars use an abbreviated pathway under Section 351(k).

Why it matters for traders

BLA milestones (submission, acceptance, decision) are major catalysts for antibody, vaccine and gene therapy developers. Watch for manufacturing language in CRLs: a CRL citing only facility or chemistry, manufacturing and controls (CMC) issues is often viewed as more fixable than one asking for a new clinical trial.

Example

A hypothetical gene therapy company, Northwind Therapeutics (NWTX), submits a BLA reviewed by CBER and receives priority review. The FDA accepts the filing, and NWTX discloses a PDUFA date roughly eight months after submission. Shares rise as the timeline becomes concrete.

FAQ

Is a BLA harder to get approved than an NDA?

The evidence standard is comparable, but biologics often face more manufacturing scrutiny because their production process is harder to replicate.

What is a biosimilar BLA?

A 351(k) application for a product highly similar to an already approved biologic, relying partly on the original product's data.